文献速递银屑病与炎症性皮肤病皮肤感染

银屑病生物制剂与小分子药物治疗中的感染风险:BIOBADADERM登记研究

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules: BIOBADADERM registry.
PubMed 文献 · J Invest Dermatol · 2026-03-11

基于BIOBADADERM登记研究,分析4820例银屑病患者(8826个治疗周期、20829患者年随访)使用生物制剂和口服小分子药物后总体、严重及特殊关注感染的发生率,以阿达木单抗为对照采用倾向评分分析计算校正发生率比。结果显示严重感染总体发生率低(5.33%),英夫利西单抗最高;

要点

  • 严重感染总体发生率低(5.33%),英夫利西单抗发生率最高。
  • 瑞莎珠单抗、乌司奴单抗总体感染风险显著低于阿达木单抗。
  • 比美吉珠单抗、布罗达鲁单抗、司库奇尤单抗、依奇珠单抗的白念珠菌感染风险显著升高。

核心结论

  • 生物制剂和小分子药物在银屑病中总体安全性良好,尤其是严重感染方面。
  • 不同药物在总体感染、呼吸道感染、COVID-19及白念珠菌感染风险上存在差异。

研究设计与样本

  • 基于BIOBADADERM登记研究的数据分析,纳入4820例患者、8826个治疗周期、20829患者年随访。
  • 以阿达木单抗为对照,采用倾向评分分析计算校正发生率比。

主要发现

  • 严重感染总体发生率为5.33%,英夫利西单抗严重感染发生率最高。
  • 最常见的严重感染为肺炎,其次为COVID-19肺炎和蜂窝织炎;非严重感染以呼吸道感染最常见,其次为COVID-19和尿路感染。
  • 瑞莎珠单抗和乌司奴单抗总体感染风险显著低于阿达木单抗(P < .002)。
  • 比美吉珠单抗、布罗达鲁单抗、司库奇尤单抗和依奇珠单抗的白念珠菌感染风险显著升高。
  • 古塞奇尤单抗、司库奇尤单抗、依奇珠单抗和乌司奴单抗呼吸道感染发生率降低;依奇珠单抗COVID-19感染风险降低,富马酸二甲酯升高。

关键数值与推荐

  • 严重感染总体发生率5.33%。
  • 瑞莎珠单抗和乌司奴单抗总体感染风险低于阿达木单抗,P < .002。

临床怎么用

  • 银屑病系统治疗选择时可将感染风险谱纳入考量,严重感染风险总体较低。
  • 对有呼吸道感染或白念珠菌感染风险顾虑者,可参考不同药物的风险差异进行个体化选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infections are the most common adverse events associated with systemic treatment for psoriasis. Using data from the BIOBADADERM registry, we analyzed incidence rates of overall, serious, and special-interest infections associated with biologics and oral small molecules. Adjusted incidence rate ratios were calculated using propensity score analysis, with adalimumab as the comparator. The study included 4820 patients (8826 treatment cycles; 20,829 patient years of follow-up). The overall incidence of serious infections was low across all treatments (5.33%), with infliximab showing the highest incidence rate. The most frequent serious infections were pneumonia, followed by COVID-19 pneumonia and cellulitis. Among nonserious infections, respiratory tract infections were most common, followed by COVID-19 and urinary tract infections. Risankizumab and ustekinumab were associated with significantly lower risk of overall infections than adalimumab (P < .002). The risk of Candida infections was significantly higher with bimekizumab, brodalumab, secukinumab, and ixekizumab. Guselkumab, secukinumab, ixekizumab, and ustekinumab were linked to reduced incidence of respiratory infections. Ixekizumab was associated with a lower risk of COVID-19 infection, whereas dimethyl fumarate showed an increased risk compared with adalimumab. Overall, our findings support the favorable safety profile of biologics and small molecules in psoriasis, particularly regarding serious infections.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Olivares-Guerrero M, González-Quesada A, Sahuquillo-Torralba A, et al. Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules: BIOBADADERM registry. J Invest Dermatol. 2026. PMID: 41825623. doi:10.1016/j.jid.2026.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。